%0 Journal Article
%T Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality
%A Kristina Mirabeau-Beale
%A Ming-Hui Chen
%A Anthony V. D'Amico
%J ISRN Oncology
%D 2014
%R 10.1155/2014/736163
%X Purpose. We evaluated the impact a prior cancer diagnosis had on the risk of prostate-cancer-specific mortality (PCSM) and all-cause mortality (ACM) in men with PC. Methods. Using the SEER data registry, 166,104 men (median age: 66) diagnosed with PC between 2004 and 2007 comprised the study cohort. Competing risks and Cox regression were used to evaluate whether a prior cancer diagnosis impacted the risk of PCSM and ACM adjusting for known prognostic factors PSA level, age at and year of diagnosis, race, and whether PC treatment was curative, noncurative, or active surveillance (AS)/watchful waiting (WW). Results. At a median followup of 2.75 years, 12,453 men died: 3,809 (30.6%) from PC. Men with a prior cancer were followed longer, had GS 8 to 10 PC more often, and underwent WW/AS more frequently ( ). Despite these differences that should increase the risk of PCSM, the adjusted risk of PCSM was significantly decreased (AHR: 0.66 (95% CI: (0.45, 0.97); ), while the risk of ACM was increased (AHR: 2.92 (95% CI: 2.64, 3.23); ) in men with a prior cancer suggesting that competing risks accounted for the reduction in the risk of PCSM. Conclusion. An assessment of the impact that a prior cancer has on life expectancy is needed at the time of PC diagnosis to determine whether curative treatment for unfavorable-risk PC versus AS is appropriate. 1. Introduction While favorable-risk (PSA ¡Ü 20; T2b category or less; Gleason score ¡Ü 7 [1]) prostate cancer (PC) can have a long natural history [2] and is often curable, unfavorable-risk PC (which comprises approximately 20% of cases) accounts for the majority of prostate cancer deaths [3]. Men of PC bearing age are also at risk for a metachronous cancer (i.e., history of or subsequent diagnosis of another cancer). When considering life expectancy in men with PC, competing risks are particularly relevant in men with favorable-risk disease [4¨C10], in order to avoid overtreatment of PC where the potential toxicities of treatment can be sustained with no prolongation in survival. To our knowledge, no study has investigated the impact that the comorbidity of a prior cancer has on the risk of PCSM. Therefore, we used a SEER population database registry to evaluate the impact that a prior cancer had on the risk of PCSM and all-cause mortality (ACM) in men with newly diagnosed, node negative, nonmetastatic PC, adjusting for age at and year of diagnosis, race, initial treatment (curative or noncurative) or active surveillance (AS) or watchful waiting (WW), and known PC prognostic factors. 2. Methods 2.1. Patients Selection
%U http://www.hindawi.com/journals/isrn.oncology/2014/736163/